Group 1 - The Trump administration has reached a deal with Johnson & Johnson to lower the prices of certain medications, aiming to enhance affordability for consumers [1] - The agreement is part of a broader initiative to address prescription drug costs, which have been a significant concern for many Americans [1] - Johnson & Johnson is expected to implement price reductions on specific drugs, although the exact medications and the extent of the price cuts have not been detailed [1] Group 2 - This deal reflects ongoing efforts by the government to negotiate better pricing with pharmaceutical companies, which may influence future pricing strategies across the industry [1] - The collaboration with Johnson & Johnson could set a precedent for similar agreements with other pharmaceutical companies, potentially reshaping the competitive landscape [1] - The administration's focus on drug pricing is likely to impact public perception and trust in pharmaceutical companies, as affordability becomes a key issue for consumers [1]

为医疗机构发放医保结余留用资金。 转自：草原云 下一步，乌兰察布市医保部门将持续规范医疗机构采购行为，稳步提升药品耗材网采率和配送率，并通 过深化医保支付方式改革、优化基层医保支付政策、构建高效医保结算服务等举措，助力基层医疗机构 高质量发展。各医疗机构将不断优化处方开具流程，强化药品配备保障，提升药事服务能力和基层诊疗 水平，发挥好"健康守门人"作用，助力分级诊疗和医防融合体系建设，切实让群众的获得感成色更足、 幸福感更可持续、安全感更有保障。 1月7日，记者从乌兰察布市医疗保障局举办的2025年度药品集中采购医保结余留用资金发放仪式上获 悉，为落实国家组织药品集中带量采购政策，及时足额兑现结余留用资金，激励公立医疗机构积极参与 药品集采、优先使用中选药品，切实减轻群众医药费用负担，乌兰察布市医疗保障局为乌兰察布市中心 医院、乌兰察布市中医蒙医医院、四子王旗人民医院等172家医疗机构发放1997万余元集采药品结余留 用医保资金。 "十四五"期间，乌兰察布市医疗保障局坚持以保障人民群众健康为中心，以降低虚高药价、减轻群众用 药负担、规范流通秩序、保障临床供应为核心目标，常态化制度化落实药品集中带量采购改革任务 ...

Core Investment Insights - Investing in blue chip stocks is recommended for building a solid portfolio that can provide stability and long-term growth [1] - Novartis, Home Depot, and American Express are highlighted as strong investment options across different sectors, offering diversification and reasonable pricing [2] Novartis - Novartis has seen a stock price increase of 46% over the past five years and offers a dividend yield of 2.9%, significantly higher than the S&P 500 average of 1.1% [4] - The company is actively pursuing growth through mergers and acquisitions, with a forecasted compounded annual growth rate of 5% to 6% through 2030, supported by a pipeline of over 30 promising medicines [5] - The stock is trading at a modest price-to-earnings ratio of 19, compared to the S&P 500 average of 26, making it an attractive option for value, growth, and dividends [6] Home Depot - Home Depot is a leading name in the home improvement sector, benefiting from new home construction and maintenance needs of home buyers [7] - The company anticipates a sales growth of 3% for the current fiscal year, despite a general consumer trend of reducing discretionary spending, indicating potential for higher growth under favorable economic conditions [9]

By making the Critical Minerals list, silver is now regarded as a strategic US asset. Therefore, policies to incentivize and protect domestic production and supply chain inviolability are given top priority on the federal level. As a result, companies engaged with tracking silver prices and production should benefit greatly by this elevated status and focus. The US Geological Survey (USGS) is issued by the Department of the Interior, and the Interior Secretary is Doug Burhum, former governor of North Dakota ...

Company Overview - Beximco Pharmaceuticals is a leading manufacturer and exporter of medicines based in Bangladesh, incorporated in 1976 [2] - The company initially imported products from Bayer, Germany, and Upjohn, USA, before starting its own manufacturing in 1980 under licensing arrangements [2] - Beximco Pharma launched its own formulation brands in 1983 and has been committed to providing access to contemporary medicines globally [2] Stock Performance - Beximco Pharmaceuticals' stock increased by 5.9%, with shares last traded at GBX 45 [1][4] - The stock crossed above its fifty-day moving average of GBX 41.80 during trading, reaching a high of GBX 45 [4] - The company has a market capitalization of £200.75 million and a price-to-earnings ratio of 0.03 [1] Financial Ratios - Beximco Pharmaceuticals has a debt-to-equity ratio of 12.47, indicating a high level of debt compared to equity [1] - The current ratio stands at 2.13, suggesting good short-term financial health, while the quick ratio is at 0.37 [1] - The fifty-day moving average price is GBX 41.80, and the two-hundred-day moving average price is GBX 42.40 [1]

alengo / E+ via Getty Images One question about how likely a company is to raise its dividend next year is whether it has already raised it for decades. If one is willing to posit that, several companies are likely candidates. 24/7 Wall St. Key Points These four companies have increased their dividends annually for decades. And they will mostly likely boost their payouts again in the coming year. If you’re thinking about retiring or know someone who is, there are three quick questions causing many ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans. ...

Core Insights - Viatris Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9 a.m. PT / 12 p.m. ET [1] - A live webcast of the presentation will be available, along with an archived version for a limited time [2] Company Overview - Viatris is a global healthcare company that bridges the gap between generics and brand-name medications, aiming to address healthcare needs worldwide [3] - The company provides access to high-quality medicines for approximately 1 billion patients annually, covering a wide range of health conditions from birth to end-of-life care [3] - Viatris has a diverse portfolio of medicines and a unique global supply chain, with headquarters in the U.S. and global centers in Pittsburgh, Shanghai, and Hyderabad [3]

Core Insights - Sanofi has made its Q4 2025 Aide memoire available on its website to assist in financial modeling of the Group's quarterly results [1] - The document includes reminders on non-comparable items, foreign currency impact, and share count [1] - Sanofi's Q4 and full year 2025 results are scheduled for publication on January 29, 2026 [1] Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives and delivering growth [2] - The company leverages its understanding of the immune system to develop medicines and vaccines for millions globally [2] - Sanofi aims to address urgent healthcare, environmental, and societal challenges through its innovative pipeline [2] Stock Information - Sanofi is listed on EURONEXT under the ticker SAN and on NASDAQ under the ticker SNY [3]

INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and ...